Mariano Provencio, MD, PhD, presented the results of CheckMate 77T as a late-breaking abstract at ASCO 2025.
Immunotherapy in Non-Small Cell Lung Cancer
Advertisement
Patrick M. Forde, MD, presented the late-breaking abstract during an oral abstract session at the 2025 ASCO Annual Meeting.
Researchers tested Dato-DXd for safety and tolerability in patients with advanced NSCLC.
Ivonescimab plus chemotherapy “demonstrated a statistically significant and clinically meaningful improvement” in PFS.
Study Highlights Relationship Between Lipid Metabolism, NK Cells in the NSCLC Tumor Microenvironment
Study investigators suggested there may be a “promising therapeutic strategy for advancing NK cell-based immunotherapy."
The study explored the effect of immune checkpoint inhibition on real-world patients with NSCLC versus trial patients.
Solange Peters, MD, PhD, presented results from the trial evaluating tiragolumab plus atezolizumab.
Ivonescimab plus chemotherapy “demonstrated strongly positive results” as a first-line treatment for advanced squamous ...
A recent study may provide a "clearer, more individualized" understanding of progression risk after discontinuation.
Stephen V. Liu, MD, weighs in on the data from the preplanned interim analysis that was recently published in The Lancet.
Subcutaneous pembrolizumab may be “a viable treatment option" in indications where pembrolizumab is approved.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.